AKBA Akebia Therapeutics Inc

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.

$0.32  -0.01 (-2.15%)
As of 05/23/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/20/2014
Outstanding shares:  183,533,075
Average volume:  9,262,051
Market cap:   $60,602,621
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKKMP44
Valuation   (See tab for details)
PE ratio:   -0.22
PB ratio:   0.75
PS ratio:   0.27
Return on equity:   -1,055.60%
Net income %:   -123.64%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy